Transposon Therapeutics
Novel NRTIs, PKR
clearingsmall molecule
Loading
Загрузка раздела...0-100 chain-logic scale · 15 dimensions · scored on public evidence
All companies
C-9DIE
Novel NRTIs, PKR
0-100 chain-logic scale · 15 dimensions · scored on public evidence
ALS ONE's 7th Annual ALS ONE Research Symposium, held November 13, 14, and 15, 2024, hosted by our research team: Dr’s Merit Cudkowicz, MD, MSc of MGH, Robert H Brown, Jr. MD, DPhil of UMass Medical School, James Berry, MD, MPH of MGH, Sabrina Paganoni, MD, PhD of MGH, and Fernando Vieira, MD of ALS TDI, and in collaboration with Indu Navar and EverythingALS for Day 3's Neurotechnology Day. The conference had over 900 registered guests from 37 countries, including researchers, scientists, and members of the ALS community from around the world, convening virtually for 3 days (Day 1: Keynote Speakers, Day 2: ALS Industry Day, Day 3: Neurotechnology Day), of sharing critical research that is underway across the globe to help uncover therapeutic options leading to an ultimate cure for Amyotrophic Lateral Sclerosis (ALS). Recordings were made of the presentations which we are/were approved to share. IN THIS VIDEO: Symposium Segment (Day 2): ALS Industry Day Presentations Title: A Phase
A phase 2a multi-center, open-label single dose level study of TPN-101 in Patients with Aicardi-Goutières Syndrome (AGS)
This is a Phase 2a study to assess the safety and tolerability of TPN-101 patients with PSP.
This is a Phase 2a study to assess the the safety and tolerability of TPN-101 in patients with Amyotrophic Lateral Sclerosis (ALS) and/or Frontotemporal Dementia (FTD) Associated with Hexanucleotide Repeat Expansion in the C9orf72 gene (C9ORF72 ALS/FTD).
Advisory Boards - Transposon Therapeutics, Inc. Copyright © . Transposon Therapeutics, Inc. All rights reserved. Privacy Policy Terms of Use ✕ Home Science Pipeline TPN-101 PSP ALS/FTD AD Novel NRTIs PKR Team News/Literature Connect ☰ --> Science Pipeline Team News / Literature Connect ‹ Team › Advisory Boards Scientific Advisory Board John Sedivy, PhD Chair Brown University Kathy Burns, MD PhD DFCI, Harvard Med School George Church, PhD Harvard University Josh Dubnau, PhD SUNY at Stony Brook Rusty Gage, PhD Salk Institute Molly Gale Hammell
Multiple System Atrophy Research News | # Update from iRegene Therapeutics
John Pacifico - Canaan Team Companies About Latest Contact Careers Canaan Build LP Portal Resources The WoVen Podcast Canaan on Twitter Canaan on LinkedIn © Copyright 2026 Canaan | Legal Team Companies About Latest Operations John Pacifico General Partner, COO + CFO / East Coast Since 2018 With nearly 25 years of experience as a venture capitalist and CEO of two healthcare companies, John brings a wide-ranging perspective to Canaan. John initially joined Canaan in 2000 as a healthcare investor and served interim roles in Canaan portfolio companies before being named CEO of Abyrx (formerly
Transposon Therapeutics Inc. - Page 1 | BioWorld BioWorld. Link to homepage. BioWorld BioWorld Science BioWorld Asia Data Snapshots Biopharma Medical technology Infographics: Dynamic digital data analysis Index insights NME Digest Special reports Infographics: Dynamic digital data analysis BCI Ebola outbreak Hantavirus Trump administration impacts Med-tech outlook 2026 Under threat: mRNA vaccine research BioWorld at 35 Biopharma M&A scorecard Bioworld 2025 review BioWorld MedTech 2025 review BioWorld Science 2025 review Women's health China's GLP-1 landscape PFA re-energizes afib m
John Pacifico: Profile, Experience & Investments | Startup Intros Skip to content How It Works Pricing Blog Events Partners Search orgs, people, news, resources... ⌘K Sign In Get Started → Search organizations, people, news, resources, and content... / How It Works Pricing Blog Events Partners Sign In Get Started → Loading people... The OS for early-stage founders from day zero to raise. Subscribe Product How It Works Pricing Partners Resources Blog Events Contact Company About Privacy Terms © 2026 Startup Intros, Inc. San Francisco, CA · Made for Founders Home / People / John Pacifico § I
Pharmaceutical Industry Mergers & Acquisitions Roundup | Contract Pharma Continue to Contract Pharma Magazine Latest Issues Latest Issues Explore recent issues of Contract Pharma covering key industry trends. View all Digital Edition Digital Edition Read the full digital version of our magazine online. View all CEO Profiles CEO Profiles Behind every facility expansion, technology investment, and quality milestone in the CDMO sector is a leadership team making deliberate choices about where to focus, how to grow, and when to take calculated risks. View all Subscribe Now Subscribe Now Stay i … l Partners entered into a definitive agreement under which CVC Capital Partners Fund IX will acquire the company’s Therakos business . Date of announcement: August 7, 2024 Value: $925 million AbbVie—Cerevel Therapeutics AbbVie completed its acquisition of Cerevel Therapeutics —strengthening its foundation in neuroscience and positioning itself to deliver sustainable long-term performance. Date of announcement: August 2, 2024 Value … .4 billion EQT—CluePoints The EQT Healthcare Growth Strategy and the EQT Growth Fund agreed to acquire a majority stake in CluePoints , with meaningful reinvestment from the management team and existing shareholders Summit Partners and Clinimetrics SA. Date of announcement: June 12, 2024 Value: undisclosed Aterian Investment Partners—CPL One of Aterian Investment Partners’ affiliates closed its acquisition of Contract Pharmaceuticals Ltd. Canada , a North American contract de
Privacy Policy - Transposon Therapeutics, Inc. Copyright © . Transposon Therapeutics, Inc. All rights reserved. Privacy Policy Terms of Use Return to Website Privacy Policy Last Updated: November 30, 2022 This Privacy Policy (" Policy ") describes how Transposon Therapeutics, Inc., and its affiliates (collectively, "Transposon" " we " " us " or " our ") collects, uses, and discloses information related to the users of the website (" Website ") and any other related and connected platforms and other online interactions where a link to this Policy is provid … icy is provided (collectively, the " Services "). However, this Policy does not apply to any research activities including enrolling or participating in clinical research or trials. Your use of our Services is subject to the Terms of Use, available at https://www.transposonrx.com/termsofuse.html , which includes applicable terms governing limitations on liability and the resolution of disputes. By using the Services, you accept and agree to the practices described in this Pol … ss, web browser type, operating system version, phone carrier and manufacturer, application installations, device identifiers, mobile advertising identifiers, and push notification tokens. Communications: direct communication, web forms, online polls, or interactions with our blogs and posts. Usage data: internet or other electronic network activity information including, but not limited to, browsing history, search history, and information regarding a consumer's interaction … y, and information regarding a consumer's interaction with an Internet website, application, or advertisement. Location data: location information about a particular individual or device, general location information (for example, your IP address may indicate your more general geographic region). Sources of Personal Information. We may collect Personal Information about individuals: Directly from you: such as when you access our website, participate in contests and promotions … information we get from a third-party with information we already have. If you submit any Personal Information relating to other people to us, you represent that you have the authority to do so and have informed that other person about the contents of this Policy. Disclosure of Personal Information We may share or disclose the Personal Informati
Lu Han - Creative Destruction Lab Unlocking Enterprise Productivity Through AI: CDL’s Putting AI to Work Program × About Program Streams Locations Staff Putting AI to Work CDL Research Streams Prime (General) Advanced Therapies AgriFood Artificial Intelligence Biomedical Engineering BioTech Cancer Climate Computational Health Compute Defence Digital Society Energy Health Health & Wellness Healthcare Robotics Manufacturing Minerals Neuro Next Gen Computing Oceans Quantum Risk Space Supply Chain Web3 Locations Berlin Calgary Cleveland Doha Estonia Halifax London Melbourne Milan Montre … xas Toronto Vancouver Wisconsin Mentors Companies Partners Blog Community EN FR Apply About Program Streams Locations Staff Putting AI to Work CDL Research Streams Prime (General) Advanced Therapies AgriFood Artificial Intelligence Biomedical Engineering BioTech Cancer Climate Computational Health Compute Defence Digital Society Energy Health Health & Wellness Healthcare Robotics Manufacturing Minerals Neuro Next Gen Computing Oceans Quantum Risk Space Supply Chain Web3 … xas Toronto Vancouver Wisconsin Mentors Companies Partners Blog Community EN FR Apply Role: Associate Sites: CDL-Rockies, CDL-Toronto, CDL-Vancouver Stream: Cancer Lu Han Partner, Lumira Ventures Role: Associate Sites: CDL-Rockies, CDL-Toronto, CDL-Vancouver Stream: Cancer Lu is science driven-investor who is passionate about helping entrepreneurs build truly innovative first-in-class life science companies. Having started as an analyst, today Lu is a Partner at Lumira, focus
PrimeFour Therapeutics - BioPharmGuy About Directory Promoted Listings Purchase Data Drug Pipelines Data Licensing Weekly Update Newsletter Contact PrimeFour Therapeutics is defunct. Assets Acquired by Transposon Therapeutics, Nov 2024 ---------------------------------------- If you believe any of this information is incorrect, please let us know . If you would like in depth information on the active companies in our directory, please check out our data purchase page to learn more about the data fields we have and how the purchasing process works. We are always happy to answer any questions so
Transposon Therapeutics, Inc. - Drug pipelines, Patents, Clinical trials - Synapse Products Data Feature Plans Request Demo Sign Up for Free Last update 08 May 2025 Transposon Therapeutics, Inc. Startups | Holding Company | 2019 | Connecticut, United States | 10-50 | www.transposonrx.com Startups | Holding Company | 2019 | Connecticut, United States | 10-50 | www.transposonrx.com Last update 08 May 2025 Overview Pipeline Deal Translational Medicine Profit Grant & Funding(NIH) Investment Financing Overview Tags Other Diseases Congenital Disorders Nervous System Diseases Small molecule drug … itions of over 360K organizations with Synapse. login or view full example data Grant & Funding(NIH) Access more than 2 million grant and funding information to elevate your research journey. login or view full example data Investment Gain insights on the latest company investments from start-ups to established corporations. login or view full example data Financing Unearth financing trends to validate and advance investment opportunities. login or view full example data
JavaScript is disabled In order to continue, we need to verify that you're not a robot. This requires JavaScript. Enable JavaScript and then reload the page.
Transposon Acquires Nucleoside Analogs Sign In For User Subscribe Latest News Interview & Opinions Pharma Events For Leaders For Marketers AI in Pharma Magazine Pharma Manufacturing Research Papers HR in Pharma Knowledge Hub Guides Advertise with Us Podcasts Sign in Subscribe Sign in Latest News Interview & Opinions Pharma Events For Leaders AI in Pharma Magazine > latest-news Transposon Therapeutics Boosts Oncology Pipeline With Acquisition Of Novel Nucleoside Analogs Transposon Therapeutics acquires PrimeFour's nucleoside analogs to target cancer and neurodegenerative disease … t Your Company Our Contributors Research Papers Advisory Team Contact Us Pharma Application Contribute Write for Us Submit your PR Join as Advisor Download App Follow Us Have any questions about Pharma Now? What is Pharma Now? Pharma Now is a leading monthly B2B magazine focused on delivering in-depth content related to the pharmaceutical and biopharma sectors. It covers the latest trends, technological innovations, leadership insights, market developments, and interviews wit … Yes, Pharma Now welcomes contributions from industry experts. Contributors can submit articles, thought leadership pieces, and case studies. You can register on the contributors' page to submit content and gain recognition for your insights. What advertising opportunities are available with Pharma Now? Pharma Now offers multiple advertising packages tailored to help companies promote their products, services, and innovations. From full-page ads to special event coverage
Jonathan Behr - SV Health Investors Strategy Therapeutics Healthcare Growth Medtech People Portfolio News Contact Investors SV8 Biotech Fund SV7+ Growth Fund Dementia Discovery Fund-2 SV Biotech Crossover Opportunities Fund SV7 Impact Medicine Fund SV7 Growth Fund Dementia Discovery Fund-1 SV Life Sciences Funds 5-6 SV Fund IV Continuation Fund SV Life Sciences Funds 3-4 ← Back to Team Jonathan Behr Partner title"/> title"/> Jonathan Behr, Ph.D., joined SV Health Investors in 2019, bringing over 18 years of venture and venture creation experience. He co-leads the Dementia Discovery Fund ( … s (acquired by MRK). Previously, Jon was the first Managing Director of the T1D Fund, where he built the fund’s investment strategy, team, and portfolio, leading to notable successes such as Inversago Therapeutics (acquired by NVO), Pandion Therapeutics (PAND, acquired by MRK), Provention Bio (PRVB, acquired by SNY), and Semma Tx (acquired by VRTX). Before that, he served as Market Sector Leader and Executive in Residence at Partners Healthcare Innovation (now Mass General Br
Brent Ahrens - Canaan Team Companies About Latest Contact Careers Canaan Build LP Portal Resources The WoVen Podcast Canaan on Twitter Canaan on LinkedIn © Copyright 2026 Canaan | Legal Team Companies About Latest Healthcare Brent Ahrens General Partner / West Coast Since 1999 Brent leads investments in an array of healthcare companies, with a focus on biopharma and medtech. Prior to joining Canaan, Brent worked in both commercial and technical roles at General Surgical Innovations, Ethicon Endo-Surgery (J&J), and IAP Research. He also has several surgical instrument patents to his cr … reimbursement idea for antibiotics Fierce Biotech: Canaan unveils $800 million fund for fresh wave of biotech bets Reuters: Semnur Pharmaceuticals announces successful Phase 1/2 trial for its lead product Fierce Biotech: Iterum bags $65m for Phase 3 trial of ex-Pfizer antibiotic We met the dynamic duo. (And they weren’t wearing capes.) Brent in 5 Origins: Born in Ohio Travel: Enjoy traveling around this great country - & others too! Talent: Used to know how to fix cars D
ADDF invests in Transposon Therapeutics' TPN-101 for Alzheimer's | Alzheimer's Drug Discovery Foundation posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By
Biopharmaceutical Archives - Lumira Ventures | Venture Capital Life Sciences | Canada Skip to content navbar-toggler Home About Lumira Ventures Foundation Team Our Team Venture Fellows Portfolio News EN FR EN Login Axonis Therapeutics Sector: Biopharmaceutical Axonis Therapeutics Axonis is advancing breakthrough discoveries to develop first-in-class therapies in order to rescue nervous system functions for neurological disorders. SpectraWAVE SpectraWAVE is revolutionizing coronary artery disease treatment through its innovative HyperVue Imaging System to provide unparalleled insights for optim
Other news to note for Nov. 30, 2020 | 2020-11-30 | BioWorld BioWorld. Link to homepage. BioWorld BioWorld Science BioWorld Asia Data Snapshots Biopharma Medical technology Infographics: Dynamic digital data analysis Index insights NME Digest Special reports Infographics: Dynamic digital data analysis BCI Ebola outbreak Hantavirus Trump administration impacts Med-tech outlook 2026 Under threat: mRNA vaccine research BioWorld at 35 Biopharma M&A scorecard Bioworld 2025 review BioWorld MedTech 2025 review BioWorld Science 2025 review Women's health China's GLP-1 landscape PFA re-ener
Transposon Therapeutics Stock Price, Funding, Valuation, Revenue & Financial Statements Technology Vendors Recent Research Newsletter Media Support Login Who We Serve Function Corporate Strategy Corporate Venture Capital Venture Capital IT Corporate Innovation How VCs Use CB Insights Go to the video gallery → Industries Consumer & Retail Tech Insurance Healthcare Industrials Financial Services Professional Services Professional Services Learn More → Success Stories How We Help Understand Tech Markets Anticipate Competitor Strategy Determine Tech Strategy Connect with Tech Vendors & … rces 7/15/2024 Debt $4.68M Undisclosed Investors $XXM 0 FY undefined 1 1/1/2024 Grant $XXM Subscribe to see more $XXM 0 FY undefined 10 1/12/2023 Series A - II $XXM Subscribe to see more $XXM 0 FY undefined 10 12/9/2020 Series A $XXM Subscribe to see more $XXM 0 FY undefined 10 5/6/2020 Seed VC $XXM Subscribe to see more $XXM 0 FY undefined 10 Date 7/15/2024 1/1/2024 1/12/2023 12/9/2020 5/6/2020 Round Debt Grant Series A - II Series A Seed VC Amount $4.68M $XXM $XXM $XXM $XXM … mer's Drug Discovery Foundation invested in Transposon Therapeutics's Grant funding round . First funding Last Funding Investor Rounds Board Seats Type Location 1/1/2024 1/1/2024 Alzheimer's Drug Discovery Foundation 1 Grant Non-Profit Foundation New York 00/00/0000 00/00/0000 Canaan Partners Subscribe to see more Venture Capital Connecticut 00/00/0000 00/00/0000 Osage University Partners Subscribe to see more Venture Capital Pennsylvania 00/00/0000 00/00/0000 … n Partners Osage University Partners Lumira Ventures Domain Associates Rounds 1 Grant Subscribe to see more Subscribe to see more Subscribe to see more Subscribe to see more Board Seats Type Non-Profit Foundation Venture Capital Venture Capital Venture Capital Venture Capital Location New York Connecticut Pennsylvania Canada New Jersey Learn more by requesting a demo Loading... 498 Seventh Avenue 12th floor New York, NY 10018 [email protected] 212 292 3148 Follow Us On Soci
Passage BIO, Inc. (Form: 10-K, Received: 03/03/2026 07:16:41) 0001787297--12-312025FYfalse0.05P18M2021 2022 2023 2024 202510001787297country:USus-gaap:ResearchMember2025-12-310001787297country:USpasg:OrphanDrugMember2025-12-310001787297us-gaap:ResearchMember2025-12-310001787297us-gaap:ResearchMember2024-12-310001787297srt:MaximumMemberpasg:AttheMarketFacilityAgreementMember2021-03-052021-03-050001787297pasg:AttheMarketFacilityAgreementMember2025-01-012025-12-310001787297us-gaap:CommonStockMember2025-01-012025-12-310001787297us-gaap:CommonStockMember2024-01-012024-12-3100017872972025-07-142025- … 12 months (or for such shorter period that the registrant was required to submit such files).   Yes ☒ No ☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth compa … NHPs with AAVhu68 or AAV5. We have an active Investigational New Drug, or IND, application from the U.S. Food and Drug Administration, or the FDA, and approved clinical trial authorizations, or CTAs, in multiple countries for PBFT02. We are conducting our upliFT-D trial, an international, multi-center, open-label, single-arm Phase 1/2 clinical trial of PBFT02 in patients with a diagnosis of symptomatic FTD- GRN . In June 2025, we reported biomarker data from patients in our … iomarker, in patients after PBFT02 administration . ​ • Broaden the application of PBFT02 by exploring its potential in additional neurodegenerative indications . Based on initial clinical data for PBFT02 in FTD- GRN and evidence supporting progranulin’s role in neurodegeneration, we have expanded our upliFT-D trial to include FTD- C9orf72 cohorts and are exploring the therapeutic potential of PBFT02 in other diseases, including ALS and AD. We believe that o … rder , FTD- GRN , because it offer s a compelling opportunity for the effective application of a genetic medicine, by correcting the progranulin deficiency that results from disease-causing mutations in the GRN gene. We are also exploring the potential for our progranulin gene therapy candidate, PBFT02, to target other degenerative disorders, suc
JavaScript is disabled In order to continue, we need to verify that you're not a robot. This requires JavaScript. Enable JavaScript and then reload the page.
%PDF-1.3 %��������� 3 0 obj > stream x�][s%�q~?�� #y���p0���K-I�Y;���� L?���J\�I��χ��� px0�J���g��h�� ��o�? o ~RǏ? k�紐�TWMg�o ���������ӱ��O[��������Ǜ��樎O=�����o�_=� ���c� ���?~{�����c �c�fh����=쟨j�q9�!9�O�SǶ� %����\馶j��?��Y�����K��c����k����?�K��\ �~{0��Fbl�J��15�Q~NJG>�n�������%1�f'��9�� }s��_\ ,A �z�V��QTu���P >@ ܄�� JĈ�p�~��� } l�����!�a9]�z=\�A7�USC5���K[�lv�f� KߴKp �LR��/��$^�|�� ��檚f��̌�ٱ$��K�!��KJ k�8��4�Q�Ų���!�%ǐ�9���#$�n��NQs_�����4��|��?]��TC&��F=_R�]�� &�mdN��ԍ��ى}0�Rs��۳��m5%�A�)���HQ�.�={05�0I��Vb\v���92� ��v��� ce/dD���8)j��%Ă�����X5ʢ�
Checking your browser - reCAPTCHA Checking your browser before accessing pmc.ncbi.nlm.nih.gov ... Click here if you are not automatically redirected after 5 seconds.
OPN - Drugs, Indications, Patents - Synapse Products Data Feature Plans Request Demo Sign Up for Free Last update 03 Nov 2024 OPN Last update 03 Nov 2024 Basic Info Related Targets OPN Related 2 Drugs associated with OPN Chitosan Target OPN Mechanism OPN antagonists Active Org. Abbott Laboratories [+1] Originator Org. Abbott Laboratories Active Indication Varicose Ulcer [+1] Inactive Indication - Drug Highest Phase Phase 3 First Approval Ctry. / Loc. - First Approval Date - WO2022134276 Patent Mining Target OPN Mechanism - Active Org. Shanghai Jiao Tong University Originator Org. Shanghai Jiao … dated, which is crucial for advancing the scientific understanding and clinical application of this traditional medicine. AIM OF STUDY: This study aimed to identify the active constituents of QD water extract (QDWE), explore its inhibitory effects on kidney stones through in vitro and in vivo studies, and elucidate the underlying mechanisms of the OPN/CD44 axis and the NLRP3 signaling pathway to provide a full understanding of its potential as a novel treatment approach again … ctations regarding the sufficiency of its existing cash and cash equivalents to fund its planned operatings, its ability to raise additional funds, which may not be available to the Company on acceptable terms or at all, its ability to resume development of GRI-0863 and capital expenditure requirements. Actual results may differ from the forward-looking statements expressed by the Company in this press release and consequently, you should not rely on these forward-looking sta
ALS Clinical Trials and Research | "Voyager has one clinical asset, a tau-targeting antibody in a phase 1 study for Alzheimer’s disease
Motor Neuron Disease Drug Pipeline Research 2024: Comprehensive Insights About 180+ Companies and 200+ Pipeline Drugs Something went wrong Skip to navigation Skip to main content Skip to right column Yahoo Finance News Finance Sport More News Today's news World UK Weather Politics Science & Tech Lifestyle Health & Wellness Relationships Parenting Entertainment TV Reality TV Movies Celebrity Music Finance My portfolio Watchlists Markets News Screeners Industries Crypto Bank of England Property Top stocks Work and management Brexit Sport Premier League Football Formula 1 Rugby Cricket Go … onverter Crypto Stocks: Losers Screeners Saved Screeners Equity Screener Mutual Fund Screener ETF Screener Features Behind The Brand Work & Management ... UK markets open in 2h 1m UK UK US Markets Europe Markets Asia Markets Cryptocurrencies Rates Commodities Currencies UK markets open in 2h 1m FTSE 100 10,461.63 +32.78 +0.31% GBP/USD 1.3184 +0.0020 +0.15% GBP/EUR 1.1593 +0.0003 +0.03% FTSE 250 23,101.52 +175.05 +0.76% AIM 777.37 -5.22 -0.67% GOLD FUTURES 4,008.90 +0.10 +
%PDF-1.5 %���� 1 0 obj > endobj 501 0 obj > stream x��]ێ�8r}���g֊w0 tUw������.� �?`R��RyZ �@ ;A�S� $؎GF��Fw� �oE8�O*��'ъ��6���[m����i5������Ҭ�Vm�R_1��̙��e�y���b�ڦ�c/z�1�r1�Y���p1��!.��;�w�!N]�Ǔ~9�g�R��+�=�� ���_�ʗ��ı��l3ۿ�ʓ�t �n�uq�k'Cz62��|���;#dMz���Q��l�x���N���\�z�m)�[v/�$�T8��z�����0d5m.Hb�t#z�E�@h8lL �����j��m�L.�4�\��� {��C��6�����f� ~ Os6fՆs�2�E({~��O\c[o�Z0c �X%u��1 ���lb��^�A"�o������6���p.���B\�n/? ��m�.�S�qu"P ����r�n�Q�?� ��}����,3#���Hj��������;�l�.� Z;��� ��5��Ԩ̣�Mr5~P��]�w6��`��*u�v~G���A��+} ����f?����k�n� }V��:��l�Y������ w!��U[k … � �||!dH� 6 ��7�: �2�����{�Q�a0C=.'!*9��S�K��I+�,����r5G�#Ҝ��R�]�*�_�W�RFp8Ö�� ?� �rV�a�7�+F�a-q�b��a ���S�QDeDx �����������6C{I��J�X��Ұ����b9��$���~ rJ��z�|�n>� ��ŝ�A:a��vLwҲy'�" �ۢ-�R�Z�AX�����UZ�c��@��et�0��X�x+�Y"p�倴Ft�/�n2�卐,ʍ�î죓U6���s⾸{*�N�u�����+ ��O+�IJP>0�i`�|�V���M��Y5� &��Vٙ�q�Ӹ|��z���.�ʯ -0��χm�cJQG���M���Rx i-�+[:�(���0�Q� S���;���ؐ��vid!#�7��*�$l���Dؓ��x�;u���찆K�u��m���c���G�,s�xה�o�|z�o]�փ�m e���Ʀ|�0�� C�YMG�,m��/
News Archive (Prior to May 2024) | Brown Technology Innovations | Brown University Skip to Main Content Brown University Brown Technology Innovations Secondary Navigation Navigation Innovation Showcase Search Menu Site Navigation Home For Faculty & Inventors Reporting an Invention Industry Sponsored Research Intellectual Property Policies Confidentiality Agreements Consulting Agreements Brown Biomedical Innovations to Impact (BBII) For Industry & Entrepreneurs Search Brown Technologies About Our Team BTI Advisory Board Brown Innovation Fellows Innovation Showcase Strategic Plan Annua … il News Archive (Prior to May 2024) News blurbs from BTI prior to May 2024. NSF grant to Theromics for ablation therapy technology April 2024. Theromics Inc. received a $1M STTR Phase II grant from NSF for HeatSYNC™, a nano-polymer gel that enhances the effectiveness of ablation therapy of abnormal tissue and allows controlled delivery of drugs directly into soft tissue with reduced side effects. Shukla elected to AIMBE College of Fellows April 2024 … se teams of robots safely and effectively. New Yosemite-American Cancer Society Award April 2024. Yosemite, an oncology-focused venture capital firm, and the American Cancer Society have launched the Yosemite-American Cancer Society Award with an initial commitment of $13.2 million. The grant program will support research on methodologies, feasibility studies, and high-risk/high-reward projects. AtomICs wins Baylor’s 2024 New Venture Competiti … sing startup founded by Brown faculty and former grad students, won first prize in Baylor’s 2024 New Venture Competition . The technology uses a novel patented technique to harness small-molecule mixtures to store digital information. Wafik El-Deiry, MD, PhD, FACP named to the National Academy of Inventors April 2024. Wafik El-Deiry, MD, PhD, FACP, director of the Legorreta Cancer Center and associate dean for oncologic sciences, has been named to … Raimondo were among twelve finalists for the 2023–2024 MIT-Royalty Pharma Prize Competition, a program that supports female faculty entrepreneurs in biotechnology and provides them with resources to help take their ideas to commercialization. Engineering faculty meet with Helen of Troy February 2024. Representatives from Helen of Tro
XBRL Viewer Please enable JavaScript to use the EDGAR Inline XBRL Viewer.
JavaScript is disabled In order to continue, we need to verify that you're not a robot. This requires JavaScript. Enable JavaScript and then reload the page.
You need to enable JavaScript to run this app. Loading...
Tietosuojavalintasi guce guce Tietosuojasi on meille tärkeää Tietosuojavalintojasi käytetään kaikissa Yahoo-konsernin tarjoamissa sivustoissa ja sovelluksissa. Yahoo käyttää evästekäytännöstämme ."> Evästeet Evästeiden (sekä vastaavien tekniikoiden, esimerkiksi verkkotallennuksen) avulla verkkosivustojen sovellusten ylläpitäjät voivat tallentaa ja lukea laitteesi tietoja. Lue lisää evästekäytännöstämme . evästeitä seuraaviin tarkoituksiin: tarjotaksemme sivustomme ja sovelluksemme sinulle todentaaksemme käyttäjät, estääksemme roskapostia ja väärinkäytöksiä sekä toteuttaaksemme tietoturvatoimia
Altis Labs CEO Felix Baldauf-Lenschen on Competitive Advantage | Health Innovation Hub (H2i) posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to joi … s across medical technology and biotech. This week, headlines include record VC fund raises, endovascular technology, molecular glues, and more. Congratulations to all involved and let me know if I missed anything. 🔔 Paris-based private equity fund Jeito Capital has hailed the $1.2 billion it has secured as the “largest raise ever achieved” by an independent biopharma-focused European fund. 🔔Oricell Therapeutics has now raised over $110 million in its final funding round be … ns, Basilea Pharmaceutica has secured an additional US$6 million from CARB‑X to fund the first‑in‑human Phase I trial of a novel Gram‑negative antibiotic 🔔French Generare, founded in 2023, is positioning itself at the intersection of synthetic biology and artificial intelligence by tackling what many in the sector now see as a fundamental bottleneck: the lack of genuinely novel molecular data. It has raised €20m in Series A financing. 🔔neuroClues, a French-Belgian MedTech s … eneurship — further developing their ideas and exploring pathways to real-world application. Update: Please note that the current description for fellow Magdalena Mietkowska is: I am a curiosity-driven cell biologist passionate about translating basic science into innovations and real-world applications. Engaging in activities involved in setting up my own Start-Up has been one of the most exciting parts of my career. Our spin-off idea deals with providing a unique and tailor … medical centers. I'm noticing a patter: ARPA-H is operating somewhere between a grant agency and a venture fund. The PROSPR program alone funded four startups directly: Cambrian Bio ($30.8M), Transposon Therapeutics, Inc. ($22M), Linnaeus Therapeutics, Inc. ($22M), and Nula Therapeutics ($20M). These aren't five-year academic grants with publicat
PASSAGE BIO, INC._December 31, 2025 0001787297 --12-31 2025 FY false 0.05 P18M 2021 2022 2023 2024 2025 1 0001787297 country:US us-gaap:ResearchMember 2025-12-31 0001787297 country:US pasg:OrphanDrugMember 2025-12-31 0001787297 us-gaap:ResearchMember 2025-12-31 0001787297 us-gaap:ResearchMember 2024-12-31 0001787297 srt:MaximumMember pasg:AttheMarketFacilityAgreementMember 2021-03-05 2021-03-05 0001787297 pasg:AttheMarketFacilityAgreementMember 2025-01-01 2025-12-31 0001787297 us-gaap:CommonStockMember 2025-01-01 2025-12-31 0001787297 us-gaap:CommonStockMember 2024-01-01 2024-12-31 0 … 12 months (or for such shorter period that the registrant was required to submit such files).   Yes ☒ No ☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth compa … NHPs with AAVhu68 or AAV5. We have an active Investigational New Drug, or IND, application from the U.S. Food and Drug Administration, or the FDA, and approved clinical trial authorizations, or CTAs, in multiple countries for PBFT02. We are conducting our upliFT-D trial, an international, multi-center, open-label, single-arm Phase 1/2 clinical trial of PBFT02 in patients with a diagnosis of symptomatic FTD- GRN . In June 2025, we reported biomarker data from patients in our … iomarker, in patients after PBFT02 administration . ​ • Broaden the application of PBFT02 by exploring its potential in additional neurodegenerative indications . Based on initial clinical data for PBFT02 in FTD- GRN and evidence supporting progranulin’s role in neurodegeneration, we have expanded our upliFT-D trial to include FTD- C9orf72 cohorts and are exploring the therapeutic potential of PBFT02 in other diseases, including ALS and AD. We believe that o … rder , FTD- GRN , because it offer s a compelling opportunity for the effective application of a genetic medicine, by correcting the progranulin deficiency that results from disease-causing mutations in the GRN gene. We are also exploring the potential for our progranulin gene therapy candidate, PBFT02, to target other degenerative disorders, suc
Pipeline - Transposon Therapeutics, Inc. Copyright © . Transposon Therapeutics, Inc. All rights reserved. Privacy Policy Terms of Use ✕ Home Science Pipeline TPN-101 PSP ALS/FTD AD Novel NRTIs PKR Team News/Literature Connect ☰ --> Science Pipeline Team News / Literature Connect ✕ Pipeline Transposon’s robust pipeline includes novel nucleoside inhibitors of LINE-1 reverse transcriptase with TPN-101 in late-stage development for multiple indications and follow-on candidates in preclinical development, as well as Protein Kinase R inhibitors (PKRi) to target
Censavudine by Transposon Therapeutics for Progressive Supranuclear Palsy: Likelihood of Approval Skip to site menu Skip to page content Switch language: .translate --> PT Menu Search Sections Home News Analysis Features Comment & Opinion Projects Data Insights Pharma Clinical Trials Drug Manufacturers Therapy Area Cardiovascular Central Nervous System Immunology Infectious Disease Oncology Respiratory Pricing and Market Access Themes Artificial Intelligence Corporate Governance Cloud Cybersecurity Environmental Sustainability Internet of Things Robotics Social Responsibility Covid-19 Insights
Congratulations to Transposon Therapeutics Inc. on their recent readouts from Phase 2 development of TPN-101 in Patients with Progressive Supranuclear Palsy and from interim analysis of Phase 2… | Worldwide Clinical Trials LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your cho
Transposon Therapeutics acquires nucleoside analogues for cancer from Primefour | BioWorld BioWorld. Link to homepage. BioWorld BioWorld Science BioWorld Asia Data Snapshots Biopharma Medical technology Infographics: Dynamic digital data analysis Index insights NME Digest Special reports Infographics: Dynamic digital data analysis BCI Ebola outbreak Hantavirus Trump administration impacts Med-tech outlook 2026 Under threat: mRNA vaccine research BioWorld at 35 Biopharma M&A scorecard Bioworld 2025 review BioWorld MedTech 2025 review BioWorld Science 2025 review Women's health China'
We are excited to have Jazz... - Step Forward to Cure TSC Facebook Log In Step Forward to Cure TSC's Post
Transposon Therapeutics, Inc. Copyright © . Transposon Therapeutics, Inc. All rights reserved. Privacy Policy Terms of Use ✕ Home Science Pipeline TPN-101 PSP ALS/FTD AD Novel NRTIs PKR Team News/Literature Connect ☰ --> Science Pipeline Team News / Literature Connect Transformational therapies for neurodegenerative and aging-related diseases Science Pipeline Team News / Literature Connect
Transposon's TPN-101 selected for testing in HEALEY ALS trial Skip to content For Healthcare Professionals Newsletter Search Search for: Search Toggle navigation Search for: Search For Healthcare Professionals About ALS Toggle menu: About ALS What is ALS? Causes and risk factors Diagnosis Symptoms Speech problems Breathing and swallowing Pseudobulbar affect Types of ALS Familial ALS Sporadic ALS Treatments Approved treatments Experimental treatments Non-drug treatments Living with Toggle menu: Living with Living with ALS Mental health Diet Exercise Aids and adaptations Community Toggle me … l not be published. Your Name Your Email Your Comment Post Comment Recent Posts Grant funds new ALS treatment approach targeting TDP-43 pathway HEALEY ALS platform trial launches new arm testing oral therapy NUZ-001 First ALS patient dosed in study of experimental gene therapy VTx-002 New funding backs commercial readiness efforts for ALS therapy Oral therapy NUZ-001 cleared by FDA to join platform trial for ALS Recommended reading Discussion News Grant funds new ALS treatmen
How Rogue Jumping Genes Can Spur Alzheimer’s, ALS Thinking, Sensing & Behaving Aging Brain Development Childhood & Adolescence Diet & Lifestyle Emotions, Stress & Anxiety Hearing Language Learning & Memory Movement Pain Sleep Smell Taste Thinking & Awareness Touch Vision See All Diseases & Disorders Addiction Alzheimer's & Dementia Cancer Childhood Disorders Epilepsy Immune System Disorders Injury Mental Health Neurodegenerative Disorders Infectious Disease COVID-19 Neurological Disorders A-Z Therapies See All Brain Anatomy & Function Anatomy Body System … . Read this article in Spanish . About the Author Amber Dance Amber Dance is an award-winning freelance science journalist based in Southern California. She contributes to publications including PNAS Front Matter , The Scientist , and Nature . She also edits books on a variety of topics. CONTENT PROVIDED BY Knowable Magazine Knowable Magazine is an independent journalistic endeavor from Annual Reviews. Related Topics Alzheimer's Disease ALS Genetics Neurodegenerative Disorder
Transposon Therapeutics Acquired a Portfolio of Novel Nucleoside Analogs for Oncology To Enhance Development Pipeline Log in Subscribe Subscribe for the Newsletter Mobile Navigation Articles Expert Interviews Roundtable Press Releases Videos The Road To Experience Market Research Directory Close Discovery Small Molecules Biologics Advanced Therapies Manufacturing Supply Chain Clinical Trials Technologies Financing Transposon Therapeutics Acquired a Portfolio of Novel Nucleoside Analogs for Oncology To Enhance Development Pipeline Transposon Therapeutics Nov 21, 2024 PR-11-24-NI-119 Oncology Pr
TPN-101 - Transposon Therapeutics, Inc. Copyright © . Transposon Therapeutics, Inc. All rights reserved. Privacy Policy Terms of Use ✕ Home Science Pipeline TPN-101 PSP ALS/FTD AD Novel NRTIs PKR Team News/Literature Connect ☰ --> Science Pipeline Team News / Literature Connect ✕ TPN-101 TPN-101, a potent inhibitor of LINE-1 reverse transcriptase, shows promise for the treatment of neurodegenerative diseases. Transposon is developing TPN-101 (aka Censavudine) to treat neurodegenerative diseases of high unmet medical need. TPN-101 has excellent systemic an
Transposon Receives Investment from the Alzheimer's Drug Discovery Foundation to Support Advancement of TPN-101 for the Treatment of Alzheimer's Disease Accessibility Statement Skip Navigation Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact Search Search When typing in this field, a list of search results will appear and be automatically updated as you type. Searching for your content... No results found. Please change your search terms and try again. News in Focus Browse News Releases All News Releases All Public Company English-only News Re … erosity of its donors, the ADDF has awarded more than $370 million to fund 765 Alzheimer's drug discovery programs, biomarker programs and clinical trials in 21 countries. To learn more, please visit: http://www.alzdiscovery.org/ . About Transposon Transposon Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing transformational therapies for the treatment of neurodegenerative and aging-related diseases, including PSP, ALS, and … tform Login ProfNet Data Privacy Do not sell or share my personal information : Submit via [email protected] Call Privacy toll-free: 877-297-8921 Contact PR Newswire Products About My Services All News Releases Platform Login ProfNet Call PR Newswire at 888-776-0942 Terms of Use Privacy Policy Information Security Policy Site Map RSS Cookies Copyright © 2026 Cision US Inc. --> -->
Pipeline - Transposon Therapeutics, Inc. Copyright © . Transposon Therapeutics, Inc. All rights reserved. Privacy Policy Terms of Use ✕ Home Science Pipeline TPN-101 PSP ALS/FTD AD Novel NRTIs PKR Team News/Literature Connect ☰ --> Science Pipeline Team News / Literature Connect ✕ Pipeline Transposon’s robust pipeline includes novel nucleoside inhibitors of LINE-1 reverse transcriptase with TPN-101 in late-stage development for multiple indications and follow-on candidates in preclinical development, as well as Protein Kinase R inhibitors (PKRi) to target
Transposon Therapeutics’ TPN-101 to be Studied for --> Accessibility: Skip TopNav Transposon Therapeutics’ TPN-101 to be Studied for Extending Healthy Aging under ARPA-H Award for up to $22M ARPA-H PROSPR program to support the development of TPN-101 to slow aging and help people stay healthy longer March 04, 2026 07:00 ET | Source: Transposon Therapeutics, Inc Transposon Therapeutics, Inc SAN DIEGO, March 04, 2026 (GLOBE NEWSWIRE) -- Transposon Therapeutics, a biotechnology company developing therapies for the treatment of neurodegenerative and aging-related diseases, today announced t … g under the PROSPR (Proactive Solutions for Prolonging Resilience) program. The award will support a multiphase research and development program to evaluate the ability of TPN-101 to improve aging-related outcomes and other measures of overall health. The ultimate goal of PROSPR is to extend healthspan, which the agency defines as the number of years aging adults live healthy lives and enjoy overall well-being by compressing the frailty and disability that comes with aging in … at comes with aging into a shorter duration of time near the end of life. “This award represents a transformative opportunity to advance TPN-101 into an entirely new therapeutic category that targets the underlying causes of age-related disease,” said Dennis Podlesak, Chairman and Chief Executive Officer of Transposon. “With no FDA-approved therapies to extend healthspan, we believe TPN-101 has the potential to be at the forefront with a first-in-class approach to preserving
Transposon Therapeutics, Inc. Copyright © . Transposon Therapeutics, Inc. All rights reserved. Privacy Policy Terms of Use ✕ Home Science Pipeline TPN-101 PSP ALS/FTD AD Novel NRTIs PKR Team News/Literature Connect ☰ --> Science Pipeline Team News / Literature Connect Transformational therapies for neurodegenerative and aging-related diseases Science Pipeline Team News / Literature Connect
Transposon Therapeutics announces TPN-101 inclusion in HEALEY ALS trial | Transposon Therapeutics, Inc. posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Cont
Transposon Therapeutics Strengthens and Expands Development Pipeline with the Acquisition of a Portfolio of Novel Nucleoside Analogs for Oncology Accessibility Statement Skip Navigation Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact Search Search When typing in this field, a list of search results will appear and be automatically updated as you type. Searching for your content... No results found. Please change your search terms and try again. News in Focus Browse News Releases All News Releases All Public Company English-only News Releases … tform Login ProfNet Data Privacy Do not sell or share my personal information : Submit via [email protected] Call Privacy toll-free: 877-297-8921 Contact PR Newswire Products About My Services All News Releases Platform Login ProfNet Call PR Newswire at 888-776-0942 Terms of Use Privacy Policy Information Security Policy Site Map RSS Cookies Copyright © 2026 Cision US Inc. --> -->
Terms of Use - Transposon Therapeutics, Inc. Copyright © . Transposon Therapeutics, Inc. All rights reserved. Privacy Policy Terms of Use Return to Website Terms of Use Last Updated: November 30, 2022 These Terms of Use (" Terms ") apply to your use of the website (" Services ") provided by Transposon Therapeutics, Inc., and its affiliates (collectively, " Transposon ," " we ," " us " or " our "). Please read these Terms carefully and in their entirety, as they include important information about your legal rights, remedies, and obligations. By accessing … essly granted to you under these Terms are hereby reserved. License These Terms grant users a limited and non-exclusive right to use the Services, including all Content thereon. Except as indicated otherwise herein or in any additional terms or conditions, you may not reproduce, distribute, modify, create derivative works of, publicly display, publicly perform, republish, download, store, transmit, or otherwise exploit any of the Content on our Services. You hereby grant to C … any shall have no obligation of any kind with respect to any such data that you submit, post, publish, display, or transmit via the Services. You represent and warrant that you have proper authority to grant this license. User Conduct and Responsibilities As a condition of your use of the Services, you agree that you will not use the Services for any purpose that is unlawful or prohibited by these Terms. Additionally, you agree, without limitation, not to: Use any content or
Transposon Therapeutics receives investment for Alzheimer's drug | Canaan posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, y … llowers 8mo Report this post SFBN Feed: Corcept Submits Marketing Authorization Application to European Medicines Agency for Relacorilant as a Treatment for Patients with Platinum-Resistant Ovarian Cancer https://lnkd.in/gkSN-Cjr REDWOOD CITY, Calif.–(BUSINESS WIRE)–Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by … anFrancisco #Biotech #Lifescience #News Corcept Submits Marketing Authorization Application to European Medicines Agency for Relacorilant as a Treatment for Patients with Platinum-Resistant Ovarian Cancer https://sfbn.org Like Comment Share Copy LinkedIn Facebook X To view or add a comment, sign in Bio-Research.AI 1,751 followers 8mo Report this post ☢️ Orano Med and Sanofi announced that AlphaMedixTM achieved all primary efficacy endpoints in a phase 2 study for gastroentero … st 🌟Tr1X announced that the FDA has cleared its Investigational New Drug (IND) application for TRX319 in progressive multiple sclerosis (MS). This moves the company's second program into the clinic, with the Phase 1/2a dose-escalation trial slated to begin in early 2026. ✨TRX319 is an innovative, allogeneic, CAR-Tr1 Treg cell therapy—a CNS-penetrant product designed to pair targeted B-cell control with anti-inflammatory signaling. 🏆The IND clearance is supported by a new $5 … ng, with six patients currently enrolled and dosed. Prescient also submitted an application to the European Medicines Agency for trial approval, with a decision expected by mid-December 2025. Additionally, the company received Orphan Drug Designation for PTX-100 from the EMA, which would provide 10 years of market exclusivity if approved. Prescie
CURE MUSCULAR DYSTROPHY GROUP OF TN-IN (IND) | Satellos will be connecting with investors over the next few weeks at the Oppenheimer, TD Cowen and Leerink Healthcare Conferences
Transposon Announces Interim Results from a Phase 2 Study of TPN-101 for the Treatment of Progressive Supranuclear Palsy to be Presented at the AD/PD™ 2024 International Conference on Alzheimer's and Parkinson's Diseases - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Relea … Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a … Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Drug Development Transposon Announces Interim Results from a Phase 2 Study of TPN-101 for the Treatment of Progressive Supranuclear Palsy to be Presented at the AD/PD™ 2024 International Conference on Alzheimer’s and Parkinson’s Diseases November 14, 2023 | 5 min read Twitter LinkedIn Facebook Email Print Transposon Therape … sp; 2 min read · Gabrielle Masson Podcast AbbVie keeps M&A rolling, FDA’s reversal train chugs along, BIO 2026 dispatch, more June 24, 2026 · 1 min read · Jef Akst " href="https://www.biospace.com/deals/lilly-astellas-circle-sangamo-assets-as-biotech-files-for-bankruptcy" > Bankruptcy Lilly, Astellas circle Sangamo assets as biotech files for bankruptcy June 23, 2026 · 3 min read · Gabrie … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Transposon Announces Final Results from a Phase 2 Study of its LINE-1 Reverse Transcriptase Inhibitor TPN-101 for the Treatment of PSP and Interim Results from a Phase 2 Study of TPN-101 for the Treatment of C9orf72-Related ALS and/or FTD - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Pre … Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a … Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Drug Development Transposon Announces Final Results from a Phase 2 Study of its LINE-1 Reverse Transcriptase Inhibitor TPN-101 for the Treatment of PSP and Interim Results from a Phase 2 Study of TPN-101 for the Treatment of C9orf72-Related ALS and/or FTD February 13, 2024 | 9 min read Twitter LinkedIn Facebook Email Print … sp; 2 min read · Gabrielle Masson Podcast AbbVie keeps M&A rolling, FDA’s reversal train chugs along, BIO 2026 dispatch, more June 24, 2026 · 1 min read · Jef Akst " href="https://www.biospace.com/deals/lilly-astellas-circle-sangamo-assets-as-biotech-files-for-bankruptcy" > Bankruptcy Lilly, Astellas circle Sangamo assets as biotech files for bankruptcy June 23, 2026 · 3 min read · Gabrie … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Transposon Therapeutics’ TPN-101 to be Studied for Extending Healthy Aging under ARPA-H Award for up to $22M - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Transposon Therapeutics’ TPN-101 to be Studied for Extending Healthy Aging under ARPA-H Award for up to $22M March 4, 2026 | 3 min read Twitter LinkedIn Facebook Email Print ARPA-H PROSPR program to support the development of TPN-101 to slow aging and help people stay healthy longer SAN DIEGO, March 04, 2 … g under the PROSPR (Proactive Solutions for Prolonging Resilience) program. The award will support a multiphase research and development program to evaluate the ability of TPN-101 to improve aging-related outcomes and other measures of overall health. The ultimate goal of PROSPR is to extend healthspan, which the agency defines as the number of years aging adults live healthy lives and enjoy overall well-being by compressing the frailty and disability that comes with agi … at comes with aging into a shorter duration of time near the end of life. “This award represents a transformative opportunity to advance TPN-101 into an entirely new therapeutic category that targets the underlying causes of age-related disease,” said Dennis Podlesak, Chairman and Chief Executive Officer of Transposon. “With no FDA-approved therapies to extend healthspan, we believe TPN-101 has the potential to be at the forefront with a first-in-class approach to preserving … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
ALS Northwest - Join us live or virtually for our annual,... Facebook Log In ALS Northwest's Post ALS Northwest October 1, 2024 · Shared with Public Join us live or virtually for our annual, no-cost ALS Research Symposium! Learn more about one of our presenters: Dr. Nicholas Olney will provide an ALS clinical trials update at the symposium. He is the Clinical Director of the Providence ALS Center in Portland, OR. He received his medical degree at the University of California, San Francisco, completing his neurology residency at the University of California, Los Angeles. Following his resi
News News New Corporate Members Bio & Healthcare Partners Startups & Investors Benefits of KBIC Location Contact E-newsletter About us Mission statement Company search News Events Achievements Home News Oncolys BioPharma Inc. begin two Phase 2 clinical trials targeting neurodegenerative diseases --> August 16, 2021 --> 水平線 --> Oncolys BioPharma Inc. completed an exclusive licensing agreement with Transposon Therapeutics, Inc. (hereinafter, Transposon) for OBP-601 (Censavudine, TPN-101), a nucleoside reverse transcriptase inhibitor, in June 2020. The company announced that the review pr … nnounced that the review process has completed for the Investigational New Drug application (IND) submitted by Transposon to the Food and Drug Administration (FDA) for Phase 2 clinical trials in US targeting two neurodegenerative diseases. The target diseases for the two clinical trials to be started by Transposon are progressive supranuclear palsy (PSP), amyotrophic lateral sclerosis (ALS), and frontotemporal degeneration (FTD). These are designated intractable diseases for
Transposon Therapeutics Acquires Portfolio of Novel Nucleoside Analogs | Contract Pharma Continue to Contract Pharma Magazine Latest Issues Latest Issues Explore recent issues of Contract Pharma covering key industry trends. View all Digital Edition Digital Edition Read the full digital version of our magazine online. View all CEO Profiles CEO Profiles Behind every facility expansion, technology investment, and quality milestone in the CDMO sector is a leadership team making deliberate choices about where to focus, how to grow, and when to take calculated risks. View all Subscribe Now Subscrib
ALS/FTD caused by C9orf72 gene mutations improves with TPN-101 Skip to content For Healthcare Professionals Newsletter Search Search for: Search Toggle navigation Search for: Search For Healthcare Professionals About ALS Toggle menu: About ALS What is ALS? Causes and risk factors Diagnosis Symptoms Speech problems Breathing and swallowing Pseudobulbar affect Types of ALS Familial ALS Sporadic ALS Treatments Approved treatments Experimental treatments Non-drug treatments Living with Toggle menu: Living with Living with ALS Mental health Diet Exercise Aids and adaptations Community Toggle menu: … ALS, FTD disease mechanisms Improving ALS, FTD research is aim of digital tool grant program Phase 1/2 trial of imaging agent for inflammation enrolls 1st ALS patient Eledon’s Antibody, Tegoprubart, Shows Promise in ALS Phase 2 Trial Recommended reading Discussion News Phase 2 trial planned for IRX4204, targeting neuroinflammation Discussion News ATH-1105 protects against common ALS, FTD disease mechanisms Discussion News Improving ALS, FTD research is aim of digital tool gr
News / Literature - Transposon Therapeutics, Inc. Copyright © . Transposon Therapeutics, Inc. All rights reserved. Privacy Policy Terms of Use ✕ Home Science Pipeline TPN-101 PSP ALS/FTD AD Novel NRTIs PKR Team News/Literature Connect ☰ --> Science Pipeline Team News / Literature Connect ✕ Literature DeCecco M, Ito T, Petrashen AP, et al. L1 drives IFN in senescent cells and promotes age-associated inflammation. Nature. 2019;566(7742):73-78. doi:10.1038/s41586-018-0784-9 ( https://pubmed.ncbi.nlm.nih.gov/30728521/ ) Frost B, Hemberg M, Lewis J, Feany MB. … 03918/ ) Page 1 Page 2 News March 4, 2026 - Transposon - Press Release - ARPA-H Award - March 4, 2026 July 9, 2025 - Transposon Receives Investment from the Alzheimer’s Drug Discovery Foundation to Support Advancement of TPN-101 for the Treatment of Alzheimer’s Disease May 28, 2025 - Transposon Announces TPN-101 Selected for Inclusion in the Phase 2/3 HEALEY ALS Platform Trial, Building on the Success of Phase 2 Study in C9orf72-related ALS December 3, 2024 - Transposon to Pr
Board of Directors - Transposon Therapeutics, Inc. Copyright © . Transposon Therapeutics, Inc. All rights reserved. Privacy Policy Terms of Use ✕ Home Science Pipeline TPN-101 PSP ALS/FTD AD Novel NRTIs PKR Team News/Literature Connect ☰ --> Science Pipeline Team News / Literature Connect ‹ Team › Board of Directors Dennis Podlesak CEO and Chair Brent Ahrens Director Bill Harrington, MD Director Daniel Hetu, MD Director Keith Katkin Director John Pacifico Director Ashwin Ram, MD Director Eckard Weber, MD Director and Chief Innovation Officer
Management Team - Transposon Therapeutics, Inc. Copyright © . Transposon Therapeutics, Inc. All rights reserved. Privacy Policy Terms of Use ✕ Home Science Pipeline TPN-101 PSP ALS/FTD AD Novel NRTIs PKR Team News/Literature Connect ☰ --> Science Pipeline Team News / Literature Connect ‹ Team › Management Team Dennis Podlesak CEO and Chair Eckard Weber, MD Chief Innovation Officer Michael Cordingley, PhD Chief Scientific Officer Andrew Satlin, MD Chief Medical Officer Lynne Rollins Chief Financial Officer Rick Orr Head, BD and Corp Counsel W
Team - Transposon Therapeutics, Inc. Copyright © . Transposon Therapeutics, Inc. All rights reserved. Privacy Policy Terms of Use ✕ Home Science Pipeline TPN-101 PSP ALS/FTD AD Novel NRTIs PKR Team News/Literature Connect ☰ --> Science Pipeline Team News / Literature Connect Dennis Podlesak CEO and Chair Dennis is CEO / Managing Partner of Axcelius LLC and advisory partner to Domain Associates. His board service or CEO leadership has resulted in many successful exits (Tobira/Allergan, Avanir/Otsuka, Corthera/ Novartis, Rightcare Solutions/Cardinal Health, … leading company creation efforts for the firm. Previously, he founded the GHIT Fund – the world’s first public-private fund focused on development of new medicines for low- and middle-income countries. He is an inventor of multiple patents and author of over 50 scientific papers. Return to Board of Directors Eckard Weber, MD Director and Chief Innovation Officer Bringing > 30 years experience, Eckard specializes in creating biopharm companies, many of which have been acquire
Transposon Therapeutics | Alzheimer's Drug Discovery Foundation Donate Email Sign Up Search Search Submit Twitter Facebook YouTube Linkedin About Us Our Founders Staff Leadership Young Professionals Committee Our Impact Our Partners Annual Reports & Financials Careers Alzheimer's Disease What is Alzheimer's? Alzheimer's Causes Diagnosis & Treatment Alzheimer's Prevention Patient & Family Resources Research Our Research Strategy Funding Opportunities COVID-19 FAQ Diagnostics Accelerator SpeechDx Goodes Prize Our Portfolio Portfolio Highlights Reporting For Funded Projects ADDF Reports Events &a … Conditions Privacy Policy Close DONATE SIGN UP Twitter Facebook YouTube Search* Submit About Us Our Founders Staff Leadership Young Professionals Committee Our Impact Our Partners Annual Reports & Financials Careers Alzheimer's Disease What is Alzheimer's? Alzheimer's Causes Diagnosis & Treatment Alzheimer's Prevention Patient & Family Resources Research Our Research Strategy Funding Opportunities Diagnostics Accelerator Melvin R. Goodes Prize
vol.14 August 2021 New Corporate Members Bio & Healthcare Partners Startups & Investors Benefits of KBIC Location Contact E-newsletter About us Mission statement Company search News Events Achievements Home vol.14 August 2021 KOBE Biomedical Innovation Cluster newsletter vol.14 - August 2021 - vol.14 August 2021 Hello, August is the hottest month in Japan and the highest temperature is recorded in some of the area. There are many Japanese summer features, but firework is one of them. Firework is written as "花火"、”花 = Flower” & "火 = Fire", just like photo below. Large firework displa
Transposon Announces TPN-101 Selected for Inclusion in the Phase 2/3 HEALEY ALS Platform Trial, Building on the Success of Phase 2 Study in C9orf72-related ALS Accessibility Statement Skip Navigation Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact Search Search When typing in this field, a list of search results will appear and be automatically updated as you type. Searching for your content... No results found. Please change your search terms and try again. News in Focus Browse News Releases All News Releases All Public Company English-only … tform Login ProfNet Data Privacy Do not sell or share my personal information : Submit via [email protected] Call Privacy toll-free: 877-297-8921 Contact PR Newswire Products About My Services All News Releases Platform Login ProfNet Call PR Newswire at 888-776-0942 Terms of Use Privacy Policy Information Security Policy Site Map RSS Cookies Copyright © 2026 Cision US Inc. --> -->
TPN-101 | PSP Blog PSP Blog For clinicians, patients and families fighting progressive supranuclear palsy Menu Skip to content Home About Me Intro for Clinicians Intro for Patients and Caregivers Tag Archives: TPN-101 An encouraging drug trial, but caveat emptor Posted on March 20, 2024 by Dr. L. Golbe A bit over two years ago, my posts from December 19, 2021 and January 22, 2022 reported that the drug censavudine (TPN-101) was entering a Phase 2a clinical trial. Now it’s over and the results were encouraging. I choose that word carefully, and here’s why: The drug company sponsor, Tr … tein-making machinery from gaining access. The chromatin, however, does have to grant access to allow normal protein manufacture, and as we age, the chromatin starts to grant too much access. The old viral DNA can now be encoded into RNA, which our immune system promptly recognizes as foreign. The result is an inflammatory immune response that, via a variety of pathways, encourages the tau protein to misfold and aggregate. Those, of course, are the hallmarks of PSP and a coup
%PDF-1.3 %��������� 3 0 obj > stream x�]k���u��_P4�����[� ��aBK�i%��l>�Tr�)+�����4��mݳ�:%U� �}߯�h�-�.�[���_T��/y=����TW���퇾Vդ� ~� >坽���ou�٧��ן>�\�����U��?��,��:o�|�U���c���?��̶k*�k�h�^�ٹE���*=�E�(���B��F���m��d�tV��1�5���g_\����_]���� K��X����x�� �ȍ�����[^8E�g__evݢvw+��� �o��o� =Ax�RG�����\����s��RSxf�\e3/Z�@� H!��p�y�k�]Y�kKR} �lcLOpb ��a� ���D�XR R���>�MU�}\�'�1Q���)��� ���� �5'XN�ʡ�w=ǗPiǦj��"|kn���� ��>û^S���:���{j ���u��� �G���ld ��9� 35Cյc (!bJB���J�f�3de ̚,� �j" �J�Ë�R �T�k�8;j(� �Vm�ʵ��xu��қ���Ji�D��r[ñz� mD ��_1���~�7���/_���u��&'L����7ՈiE�\ Ѱ2S%�
Instagram Instagram Log In Sign Up Close Never miss a post from theaftd Sign up for Instagram to stay in the loop. Sign up Log in theaftd Verified • Follow More options theaftd Verified 105w Biotechnology company Transposon Therapeutics announced that its experimental drug for #PSP , TPN-101, has received Fast Track Designation from the @fda . The FDA is increasingly recognizing the needs of families affected by #FTD . Click the link in our bio under blog & articles to learn more. Load more comments theaftd Verified 105w #fda #psp #treatment #frontallobes #temporallobes #newblogpost #newsl
The AGSAA and Transposon Therapeutics, Inc. Collaborate To Empower Patients to Make Informed Decisions About Participation in Clinical Trials. — AGS Advocacy Association Home About About AGS About the AGSAA Contact Family Resources Clinical Trials Orientation FAQ JAK Inhibition Family And Physician Reference Clinical Care Recommendations Programs and Resources Family Planning FAQ Find a Doctor Connect to the Community Reverse Transcriptase Inhibitors Podcast Grief & Loss Portal New Page Genetics Corner Family Planning Home Accessibility Guide Projects AGS ECHO Contact Registry Citizen He … Participant Breakdown, August 2022 Aug 12, 2022 Aug 12, 2022 Introducing AGSAA Grant Awardee, Dr. Barney Viengkhou Aug 12, 2022 Aug 11, 2022 Driving Newborn Screening To The Next Stage Aug 11, 2022 Aug 9, 2022 A Helping Hand When You Need it Most Aug 9, 2022 July 2022 Jul 28, 2022 AGS Patient Registry Virtual Walkthrough, Enrolling and Participating Jul 28, 2022 Jul 20, 2022 Introducing AGSAA Grant Awardee, Dr. Jessica Garau Jul 20, 2022 Jul 17, 2022 AGS Patient Registry Int … es Mar 23, 2022 Mar 16, 2022 Request For Applications, AGSAA Young Investigator Grant Mar 16, 2022 Mar 14, 2022 Industry Partners, Promising Developments! Mar 14, 2022 Mar 8, 2022 Patient Registry - Safety of COVID Vaccination in AGS Investigation Mar 8, 2022 February 2022 Feb 28, 2022 Rare Disease Day! Rare Researcher Fundraiser! Feb 28, 2022 Feb 27, 2022 AGS Dads Unite! Feb 27, 2022 Feb 27, 2022 AGS Community Driven Innovation and the Patient Registry Feb 27, 2022 Feb 26, 2 … 27, 2022 Feb 26, 2022 Rare Disease Day Fundraiser for the AGSAA Rare Researcher Grant Feb 26, 2022 Feb 22, 2022 Next Step for the Patient Registry, a COVID/Pandemic Study Feb 22, 2022 Feb 18, 2022 Post Symposium Update Feb 18, 2022 Feb 12, 2022 Patient Registry Enrollment Picks Up Speed! Feb 12, 2022 Feb 3, 2022 AGSAA, Biogen, LunaPBC, and Genetic Alliance Launch Community-Led Discovery Program for Aicardi-Goutières Syndrome Feb 3, 2022 Feb 3, 2022 2021 ACR and EULAR Recommen
censavudine (TPN-101) / Oncolys BioPharma, Transposon Therap, Yale University censavudine (TPN-101) / Oncolys BioPharma, Transposon Therap, Yale University - LARVOL DELTA Home Next Prev 1 to 25 Of 28 Go to page 1 2 April 09, 2026 A Phase 2a Study of TPN-101 in Patients With Progressive Supranuclear Palsy (PSP) (clinicaltrials.gov) - P2 | N=42 | Completed | Sponsor: Transposon Therapeutics, Inc. | Active, not recruiting ➔ Completed | Phase classification: P2a ➔ P2 Phase classification • Trial completion • CNS Disorders • Movement Disorders • Progressive Supranuclear Palsy Print Email More shari
Alzheimer’s Drug Discovery Foundation Provides Transposon Therapeutics with Investment to support Alzheimer’s Treatment TPN-101 | PharmExec --> --> News News Academy Multimedia Editorial Podcasts Editorial Videos Peer Exchange Profiles in Medicine Shorts Conferences Conference Coverage Conference Listing More Publications Pharmaceutical Executive Partner Perspectives Resources Content Engagement Hubs E-Books Events Sponsored Podcasts Sponsored Videos Webcasts Whitepapers Subscribe My Account News Academy Multimedia Conferences Publications Partner Perspectives Resources Subscribe Corporate Com
Transposon Therapeutics, Inc. | Lifespan Research Institute Donate Login About Mission Board of Directors Scientific Advisory Board Team Annual Reports Contact Research Supported Projects Investments Publications Education Summer Scholars Post-Baccalaureate Host Lab Signup News Outlet Investor Network About Join Reports Advocacy Video Initiatives Engaging the Press Crowdfunding Sponsored Projects Advocacy Topics A4LI Resources Rejuvenation Roadmap Infographics Longevity Topics Find Longevity Events EARD Conference Archive Get Involved Donate Be a Lifespan Hero Hall of Heroes Join the Lifespan
Into the Unknown — How Artificial Intelligence Can Help Biotech Companies Chart the Dark Genome BioPharmaTrend --> Latest News AI in Bio Companies Newsletter About At a Glance Our Team Advisory Board Citations and Press Coverage Partner Events Calendar Advertise with Us Write for Us --> Login/Join AI in Bio Tech Giants Next-Gen Tools Biotech Ventures Industry Movers NeuroTech Business Intellilgence Into the Unknown — How Artificial Intelligence Can Help Biotech Companies Chart the Dark Genome by Louise von Stechow (contributor ) • June … y responsible for assuring they own any required copyright for any content they submit to BiopharmaTrend.com. This website and its owners shall not be liable for neither information and content submitted for publication by Contributors, nor its accuracy. # AI in Bio Share: With DeepMind’s release of AlphaGenome —a deep learning model that can predict the relevance of variants in both coding and non-codin … c2024) Backed by Serum Institute India, European Innovation Council (EIC) Fund - Evaxion Hørsholm, Denmark Cancer & infectious disease vaccines Endogenous retroviruses (ERVs), repetitive elements Public offering $10.8M (Jan2025) MSD/Merck: EVX‑B2/B3 options, Clin trial collaboration EVX‑01 with Keytruda; Afrigen/WHO; Gates Foundation GENeuro Geneva, Switzerland MS, ALS, long‑COVID (autoimmune/neurology) HERV‑derived Envelope proteins Debt-restructuring morato … n, Belgium & San Diego, USA Oncology lncRNAs (e.g. MALAT1) €1.7M grant (2023) Alliance with Ionis Pharma Illuminating the dark genome – How AI / ML can aid interpretation of non-coding DNA While our understanding of the dark genome and its links to disease is growing, the interpretability of genetic variation within those unmapped genetic territories remains challenging—due to the sheer amount of dark DNA and the often more subtle outcom
424B4 1 mobiamedical-424b4.htm 424B4 Document Filed pursuant to Rule 424(b)(4) Registration No. 333-295160  10,000,000 Shares Common Stock This is Mobia Medical, Inc.’s initial public offering. We are offering 10,000,000 shares of our common stock. The public offering price is $15.00 per share. Currently, no public market exists for the shares. We have been approved to list our common stock on the Nasdaq Global Select Market under the symbol ‘‘MOBI.’’ We are an “emerging growth company” and a “smaller reporting company” as defined … owing the results of our pivotal trial, we submitted a premarket approval (PMA) application to the FDA in March 2021. The Vivistim System received PMA approval from the FDA in 2021 and is classified by the FDA as a Class III device. In 2021, the Vivistim System was granted breakthrough device status under the FDA’s Breakthrough Devices Program. We aim to build upon these development efforts and leverage our internal expertise, clinical insights and experience gained fro … dure has been safely performed by neurosurgeons, who are trained on it in their residency programs, and other qualified surgeons for over 25 years to treat other medical conditions and is considered safe and reliable. Our clinical results have validated the safety of the system and therapy, with no severe adverse events, serious adverse events or unanticipated adverse events associated with the Vivistim System in our VNS-REHAB trial. Our clinical results have also validated t … y and adversely affected, and we may be unable to achieve revenue growth and to fund our operations. • If we fail to effectively hire, train, and retain our direct sales force, increase our sales capabilities, or develop broad brand awareness in a cost-effective manner, our growth will be materially and adversely affected, and our business will suffer. • Coverage and adequate reimbursement may not be available or may be subject to change for our Vivistim System, i … the adoption of some accounting standards until those standards would otherwise apply to private companies. We have elected to use the extended transition period for any other new or revised accounting standards during the period in which we remain an emerging growth company; however, we may adopt certain new or revised accounting standards e
📣 In recognition of ALS... - Muscular Dystrophy Association Facebook Log In Muscular Dystrophy Association's Post Muscular Dystrophy Association Verified account May 21 · Shared with Public In recognition of ALS Awareness Month, join us on Friday, May 29 for an on-demand webinar focused on the latest developments in ALS research, including genetic discoveries to environmental influences and important updates in clinical trials. The program will feature presentations from experts in ALS Research including: Dr. Bryan J. Traynor, Neurologist and Senior Investigator with the National Institu … al Hospital Neurological Clinical Research Institute Register for free TODAY to submit your questions and receive the link when the program is available to view: https://www.mda.org/.../new-frontiers-in-als-research... Thank you to our program supporters: Biogen , Regeneron , and Shionogi #ALS #ALSawarenessMonth #Research #MDA All reactions: 10 Like Comment
Checking your browser - reCAPTCHA Checking your browser before accessing pmc.ncbi.nlm.nih.gov ... Click here if you are not automatically redirected after 5 seconds.
%PDF-1.3 %��������� 3 0 obj > stream x�]ms��q��_�{+�"���$�toR|�,)�#�^�*u�TⲜXJ��yyz�,w���v�=��=�=��̿���߽�U���+����x�:ԭ��}�W�0�����W�yg ğ���ۺi���������U~� yY\������^�����1W]��O�w�?����k������rыs�f� U�8,͢�>e�V�M=:N�!'ӥ�v�JM]��z �/yyqy�����gW��y����X�{��=�����w�ű�>��-u��:��tq��:\�?��אַ$S8uӡ�mk�;��І�04P�\���.'CTU� �&� $P�OdK�b����~|�%�W �#2� P$"� �RZ���>�K��QU0���3'���?����o|��{ݤ����^;�lr��.�';�W�y��Uf����w�/�:��SB�)�'"�$ ��U�aҾOՍ�UάA���v�L�/ ��ŗ���d9y=��ij���Y����� ]s hz- G�I������o����iT�j ��s�@�� їtFf�E�^1l-LmЌvx�l9��աk�\�6Ҡ�תs潳(:�ا�5�ަ�d��R�-�������t�AC�f